Rigel Pharmaceuticals (RIGL) was Initiated by Piper Jaffray to “Overweight”. Piper Jaffray advised their investors in a research report released on Jun 13, 2016.
Many Wall Street Analysts have commented on Rigel Pharmaceuticals. Rigel Pharmaceuticals was Upgraded by JP Morgan to ” Overweight” on Apr 22, 2016.
On the company’s financial health, Rigel Pharmaceuticals reported $-0.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.21. The company had revenue of $5.03 million for the quarter, compared to analysts expectations of $4.00 million. The company’s revenue was up 130.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.21 EPS.
Rigel Pharmaceuticals closed down -0.03 points or -1.24% at $2.39 with 2,24,106 shares getting traded on Friday. Post opening the session at $2.38, the shares hit an intraday low of $2.36 and an intraday high of $2.47 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jun 12, 2015, Donald G Payan (EVP, Pres. Discovery&Research) sold 41,666 shares at $3.68 per share price.
Rigel Pharmaceuticals Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases immuno-oncology related diseases and muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. It has various product candidates in development: fostamatinib; R348; two oncology product candidates and two preclinical programs. Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor. R348 is a topical janus kinase (JAK)/SYK inhibitor. It is conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.